A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhe
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003150
- Lead Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) Aged >=18 years;
(2) 2019-nCoV pneumonia is diagnosed according to the standard of diagnosis and treatment;
(3) Patient's condition has reached the standard of desolation / discharge specified according to the diagnosis and treatment plan;
(4) According to the diagnosis standard, the syndrome differentiation of TCM is FeiPiQiXuZheng;
(5) Volunteer to participate in the study and sign informed consent.
(1) Known or suspected allergy to the components of the study drug;
(2) Acute infection of other viruses and bacteria has not been cured;
(3) The function of liver and kidney was abnormal (ALT/AST>=2 times of the upper limit of normal value, SCr>1.5 times of the upper limit of normal value);
(4) Participating in clinical trials of other drugs;
(5) Pregnant and lactating women; or can not take effective contraceptive measures during the trial;
(6) According to the judgment of the researcher, there are other situations that are not suitable for the experiment.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;
- Secondary Outcome Measures
Name Time Method